Multi-center phase 1B trial of ACY-1215 (Ricolinostat) combined with nab-paclitaxel in unresectable or metastatic breast cancer

Protocol: 
AAAQ3709
Phase: 
I

Multi-center phase 1B trial of ACY-1215 (Ricolinostat) combined with nab-paclitaxel in unresectable or metastatic breast cancer

To determine the MTD of ACY-1215 in combination with weekly abraxane; To evaluate the safety and tolerability of ACY-1215 in combination with weekly abraxane

Are you Eligible? (Inclusion Criteria)

To be eligible for this trial, patients must:
- have unresectable or metastatic breast cancer (all subtypes are allowed in
this study)
- be at least 18 years of age
Patients whose cancer has spread to the brain may be eligible, provided
their brain metastases are asymptomatic and stable

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States